![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pan-genotypic Hepatitis C Treatment With Glecaprevir+ Pibrentasvir Resulted in Improvement in Cardiovascular and Metabolic Extrahepatic Manifestations and Stable Renal Function: Results From Phase 3 Clinical Trials
|
|
|
Reported by Jules Levin
AASLD - Presented at the American Association for The study of Liver Diseases (AASLD), October 20 -24, 2017, Washington DC, USA
Tram T. Tran,1 Darshan Mehta,2,3Federico J. Mensa,3Caroline Park,3Yuri Sanchez Gonzalez3
1Cedars-Sinai Medical Center, Los Angeles, California, United States; 2Schaeffer Center for Health Policy and Economics, University of Southern California, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States
![1026171](../images/102717/102717-9/1026171.gif)
![1026172](../images/102717/102717-9/1026172.gif)
![1026173](../images/102717/102717-9/1026173.gif)
![1026174](../images/102717/102717-9/1026174.gif)
![1026175](../images/102717/102717-9/1026175.gif)
![1026176](../images/102717/102717-9/1026176.gif)
![1026177](../images/102717/102717-9/1026177.gif)
![1026178](../images/102717/102717-9/1026178.gif)
![1026179](../images/102717/102717-9/1026179.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|